Quantitative PCR – new diagnostic tool for quantifying specific mRNA and DNA molecules: HER2/neu DNA quantification with LightCycler real‐time PCR in comparison with immunohistochemistry and fluorescence in situ hybridization

References

• Thogersen VB, Sorensen BS, Poulsen SS, Orntoft TF, Wolf H, Nexo E. A subclass of HER1 ligands are prognostic markers for survival in bladder cancer patients. Cancer Res 2001; 61: 6227–33.
   PubMed Web of Science ®Google Scholar
• Mellon JK, Cook S, Chambers P, Neal DE. Transforming growth factor alpha and epidermal growth factor levels in bladder cancer and their relationship to epidermal growth factor receptor. Br J Cancer 1996; 735: 654–8.
   Web of Science ®Google Scholar
• de Boer WI, Houtsmuller AB, Izadifar V, Muscatelli-Groux B, van der Kwast TH, Chopin DK. Expression and functions of EGF, FGF and TGFbeta-growth-factor family members and their receptors in invasive human transitional-cell-carcinoma cells. Int J Cancer 1997; 71: 284–91.
   Google Scholar
• Normanno N, Bianco C, De Luca A, Maiello MR, Salomon DS. Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocrinol Rel Cancer 2003; 10: 1–21.
   Google Scholar
• Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplifica-tion of the HER-2/neu oncogene. Science 1987; 235: 177–82.
   PubMed Web of Science ®Google Scholar
• Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001; 61 Suppl. 2: 1— 13.
   Google Scholar
• Ross JS, Fletcher JA. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Semin Cancer Biol 1999; 9: 125–38.
   PubMed Web of Science ®Google Scholar
• Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter M, Paton V, Shak S, Lieberman G, Slamon DJ. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for meta-static disease. J Clin Oncol 1999; 17: 2639–48.
   Google Scholar
• Baselga J. Clinical trials of Herceptin (trastuzu-mab). Eur J Cancer 2001; 37 Suppl. 1: S18—S24.
   Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D, Gutheil JC, Harris LN, Fehrenbacher L, Slamon DJ, Murphy M, Novotny WF, Burchmore M, Shak S, Stewart SJ. First-line Herceptin monotherapy in metastatic breast cancer. Oncology 2001; 61 Suppl. 2: 37–42.
   Google Scholar
• Piccart M, Lohrisch C, Di Leo A, Larsimont D. The predictive value of HER2 in breast cancer. Oncology 2001; 61 Suppl. 2: 73–82.
   Google Scholar
• Bast RC, Ravdin P, Hayes DF, Bates S, Fritsche H, Jessup JM, Kemeny N, Locker GY, Mennel RG, Somerfield MR. 2000 update of recommen-dations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19: 1865–78.
   Google Scholar
• Hanna W. Testing for HER2 status. Oncology 2001; 61 Suppl. 2: 22–30.
   Google Scholar
• Pauletti G, Dandekar S, Rong H, Ramos L, Peng H, Seshadri R, Slamon DJ. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry. J Clin Oncol 2000; 18: 3651–64.
   Google Scholar
• Onody P, Bertrand F, Muzeau F, Bieche I, Lidereau R. Fluorescence in situ hybridization and immunohistochemical assays for HER-2/neu status determination: application to node-negative breast cancer. Arch Pathol Lab Med 2001; 125: 746— 50.
   Google Scholar
• Tubbs RR, Pettay JD, Roche PC, Stoler MH, Jenkins RB, Grogan TM. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001; 19: 2714–21.
   PubMed Web of Science ®Google Scholar
• de Cremoux P, Martin EC, Vincent-Salomon A, Dieras V, Barbaroux C, Liva S, Pouillart P, Sastre-Garau X, Magdelenat H. Quantitative PCR analysis of c-erb B-2 (HER2/neu) gene amplifica-tion and comparison with p185(HER2/neu) pro-tein expression in breast cancer drill biopsies. Int J Cancer 1999; 83: 157–61.
   Google Scholar
• Lehmann U, Glockner S, Kleeberger W, Feist H, von Wasielewski R, Kreipe H. Detection of gene amplification in archival breast cancer specimens by laser-assisted microdissection and quantitative real-time polymerase chain reaction. Am J Pathol 2000; 156: 1855–64.
   PubMed Web of Science ®Google Scholar
• Lyon E, Millson A, Lowery MC, Woods R, Wittwer CT. Quantification of HER2/neu gene amplification by competitive PCR using fluores-cent melting curve analysis. Clin Chem 2001; 47: 844–51.
   Google Scholar
• Offersen BY, Sorensen FB, Yilmaz M, Knoop A, Overgaard J. Chalkley estimates of angiogenesis in early breast cancer. Relevance to prognosis. Acta Oncol 2002; 41: 695–703.
   Google Scholar
• Hansen LL, Andersen J, Overgaard J, Kruse TA. Molecular genetic analysis of easily accessible breast tumour DNA, purified from tissue left over from hormone receptor measurement. APMIS 1998; 106: 371–7.
   PubMed Web of Science ®Google Scholar
• Olsen KE, Knudsen H, Rasmussen BB, Balslev E, Knoop A, Ejlertsen B, Nielsen KY, Schifinau A, Overgaard J, for the Danish Breast Cancer Co-operative Group. Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol 2004; 43: 35–42.
   Google Scholar
• Beyser K, van de Vijver M, Hanna W, Seth D, Sanchez A, Reiser A, Pedrocchi M, Lluch A, Rueschoff J. HER2-specific PCR on fixed breast cancer sections defines a similar patient population as FISH: a comparison of the LightCycler-HER2/ neu DNA quantification kit, FISH and IHC. ASCO meeting 2002. Abstract.
   Google Scholar
• O'Malley FP, Parkes R, Latta E, Tjan T, Zadro T, Mueller R, Arneson N, Blackstein M, Andrulis I. Comparison of HER2/neu status assessed by quan-titative polymerase chain reaction and immuno-histochemistry. Am J Clin Pathol 2001; 115: 504— 11.
   PubMed Web of Science ®Google Scholar
• Hanna WM, Kahn HJ, Pienkowska M, Blondal J, Seth A, Marks A. Defining a test for HER-2/neu evaluation in breast cancer in the diagnostic setting. Mod Pathol 2001; 14: 677–85.
   PubMed Web of Science ®Google Scholar
• Nichols DW, Wolff DJ, Self S, Metcalf JS, Jacobs D, Kneuper-Hall R, Cate JC. A testing algorithm for determination of HER2 status in patients with breast cancer. Ann Clin Lab Sci 2002; 32: 3–11.
   Google Scholar
• Merkelbach-Bruse S, Wardelmann E, Behrens P, Losen I, Buettner R, Friedrichs N. Current diagnostic methods of HER-2/neu detection in breast cancer with special regard to real-time PCR. Am J Surg Pathol 2003; 27: 1565–70.
   Google Scholar
• Bartlett JM, Going JJ, Mallon EA, Watters AD, Reeves JR, Stanton P, Richmond J, Donald B, Ferrier R, Cooke TG. Evaluating HER2 amplifi-cation and overexpression in breast cancer. J Pathol 2001; 195: 422–8.
   PubMed Web of Science ®Google Scholar
• Hoang MP, Sahin AA, Ordonez NG, Sneige N. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and inter-observer reproducibility in invasive breast carci-noma. Am J Clin Pathol 2000; 113: 852–9.
   PubMed Web of Science ®Google Scholar
• Thomson TA, Hayes MM, Spinelli JJ, Hilland E, Sawrenko C, Phillips D, Dupuis B, Parker RL. HER-2/neu in breast cancer: interobserver varia-bility and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization. Mod Pathol 2001; 14: 1079–86.
   PubMed Web of Science ®Google Scholar
• Jacobs TW, Gown AM, Yaziji H, Barnes MJ, Schnitt SJ. Specificity of HercepTest in determin-ing HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999; 17: 1983— 7.
   Google Scholar
• Clinical laboratory assays for HER-2/neu ampli-fication and overexpression: quality assurance, standardization, and proficiency testing Arch Pathol Lab Med 2002; 126: 803–8.
   Google Scholar
• Persons DL, Bui MM, Lowery MC, Mark HF, Yung JF, Birkmeier JM, Wong EY, Yang SJ, Masood S. Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: a multicenter portability study. Ann Clin Lab Sci 2000; 30: 41–8.
   Google Scholar
• Check W. More than one way to look for HER2. CAP Today 1999; 13: 1, 40–2, 46.
   Google Scholar
• Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC, Osborne CK, Gilchrist KW, Mansour EG, Abeloff M, Eudey L. HER-2/neu in node-negative breast cancer: prognostic signifi-cance of overexpression influenced by the presence of in situ carcinoma. J Clin Oncol 1992; 10: 599–605.
   PubMed Web of Science ®Google Scholar
• Paik S, Bryant J, Tan-Chiu E, Romond E, Hiller W, Park K. Real-world performance of HER2 testing - National surgical adjuvant breast and bowel project experience. J Natl Cancer Inst 2002; 94: 852–4.
   Google Scholar
• Bieche I, Olivi M, Champeme MH, Vidaud D, Lidereau R, Vidaud M. Novel approach to quantitative polymerase chain reaction using real-time detection: application to the detection of gene amplification in breast cancer. Intl J Cancer 1998; 78: 661–6.
   PubMed Web of Science ®Google Scholar
• Millson A, Suli A, Hartung L, Kunitake S, Bennett A, Nordberg MCL, Hanna W, Wittwer CT, Seth A, Lyon E. Comparison of two quantitative polymerase chain reaction methods for detecting HER2/neu amplification. J Mol Diagn 2003; 5: 184–90.
   PubMed Web of Science ®Google Scholar
• Gjerdrum LM, Sorensen BS, Kjeldsen E, Sorensen FB, Nexo E, Hamilton-Dutoit S. Real-time quantitative PCR of microdissected paraffin-embedded breast carcinoma—an alternative method for HER2/neu analysis. J Mol Diagn 2004; 6: 42–51.
   Google Scholar